Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study

Blood (2024) 144 (Supplement 1): 1473.

https://doi.org/10.1182/blood-2024-205776

Published: 2024

Journal Articles

A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience

Blood (2024) 144 (Supplement 1): 1488.

https://doi.org/10.1182/blood-2024-206291

Published: 2024

Journal Articles

Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 4248.

https://doi.org/10.1182/blood-2024-205329

Published: 2024

Journal Articles

Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience

Blood (2024) 144 (Supplement 1): 4249.

https://doi.org/10.1182/blood-2024-206218

Published: 2024

Journal Articles

The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Blood (2024) 144 (Supplement 1): 4297.

https://doi.org/10.1182/blood-2024-206289

Published: 2024

Journal Articles

Impact of TP53 Mutation on Survival Outcomes in Acute Lymphoblastic Leukemia at a Tertiary Center

Meera Patel, Ahmed N Mohamed, Hadil Zureigat, Emily C. Zabor, Daniel P. Nurse, Yohana B. Bedelu, Mark Jinan Chen, Joy Nakitandwe, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Sudipto Mukherjee, Hetty E. Carraway, Anjali S. Advani, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 4221.

https://doi.org/10.1182/blood-2024-199333

Published: 2024

Journal Articles

Impact of P190 and P210 BCR::ABL1 Chimeric Protein on Outcomes of Acute Lymphoblastic Leukemia at a Tertiary Center

Ahmed N Mohamed, Meera Patel, Hadil Zureigat, Daniel P. Nurse, Sara F Haddad, Emily C. Zabor, Yohana B. Bedelu, Mark Jinan Chen, Joy Nakitandwe, John C. Molina, Sophia Balderman, Akriti G. Jain, Abhay Singh, Sudipto Mukherjee, Aaron T. Gerds, Hetty E. Carraway, Anjali S. Advani, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 5909.

https://doi.org/10.1182/blood-2024-202558

Published: 2024

Journal Articles

Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study

Blood (2024) 144 (Supplement 1): 1777.

https://doi.org/10.1182/blood-2024-212146

Published: 2024

Journal Articles

Outcomes of Second-Line Tyrosine Kinase Inhibitors after First-Line Imatinib in Chronic Myelogenous Leukemia: A Retrospective Cohort Study

Muaz Alsabbagh Alchirazi, Hadil Zureigat, Ahmed N Mohamed, Aastha Dhakal, Ali Mushtaq, Naveen Rehman, Bryan Berube, Sneha Govande, Emily C. Zabor, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Anjali S. Advani, Hetty E. Carraway, Matt Kalaycio, Sudipto Mukherjee, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 6597.

https://doi.org/10.1182/blood-2024-206448

Published: 2024

Journal Articles

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 111.

https://doi.org/10.1182/blood-2024-199330

Published: 2024

Journal Articles

Evaluating Impact of Insertion Length on Clinical Outcomes in FLT3-ITD Mutated AML: A Single Center Retrospective Analysis

Blood (2024) 144 (Supplement 1): 6143.

https://doi.org/10.1182/blood-2024-209265

Published: 2024

Journal Articles

Outcomes of Accelerated and Blast Phase Chronic Myeloid Leukemia at a Tertiary Center

Ahmed N Mohamed, Hadil Zureigat, Muaz Alsabbagh Alchirazi, Aastha Dhakal, Ali Mushtaq, Naveen Rehman, Bryan Berube, Sneha Govande, Emily C. Zabor, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Anjali S. Advani, Hetty E. Carraway, Matt Kalaycio, Sudipto Mukherjee, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 6610.

https://doi.org/10.1182/blood-2024-210152

Published: 2024

Journal Articles

Outcomes of Blast-Phase MPN and JAK2 , MPL , and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2 , MPL , and CALR Genes: A Propensity Score-Adjusted Cohort Study

Blood (2024) 144 (Supplement 1): 2868.

https://doi.org/10.1182/blood-2024-207748

Published: 2024

Journal Articles

Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 2862.

https://doi.org/10.1182/blood-2024-202134

Published: 2024

Journal Articles

Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience

Blood (2024) 144 (Supplement 1): 2848.

https://doi.org/10.1182/blood-2024-202525

Published: 2024

Journal Articles

Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic

Kimberly C Jenkins, MSNM, Emily C Zabor, DrPH, Lindsey A. R. Mooney, BS, Aaron T. Gerds, MDMS, Kerry O'Hop, BS, Makenzie Guy, BA, Megan Kilbane, MBA, Nathan A Pennell, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-139937

Published: 2020

Journal Articles

RAS Pathway Mutations Are Associated with Proliferative Features and Frequently Co-Occur with TET2 mutationsin Philadelphia Negative MPN Subtypes

Bartlomiej M Getta, MBBS, Emily C Zabor, Sean Devlin, PhD, Kristina Marie Knapp, Minal Patel, BA, Abhinita Mohanty, Marcel van den Brink, MD PhD, Maria Arcila, MD, Ross L. Levine, MD, Rapaport Franck, Raajit K. Rampal, MD, PhD

Blood (2016) 128 (22): 4269.

https://doi.org/10.1182/blood.V128.22.4269.4269

Published: 2016

NARROW

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study

A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience

Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study

Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience

The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Impact of TP53 Mutation on Survival Outcomes in Acute Lymphoblastic Leukemia at a Tertiary Center

Impact of P190 and P210 BCR::ABL1 Chimeric Protein on Outcomes of Acute Lymphoblastic Leukemia at a Tertiary Center

Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study

Outcomes of Second-Line Tyrosine Kinase Inhibitors after First-Line Imatinib in Chronic Myelogenous Leukemia: A Retrospective Cohort Study

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Evaluating Impact of Insertion Length on Clinical Outcomes in FLT3-ITD Mutated AML: A Single Center Retrospective Analysis

Outcomes of Accelerated and Blast Phase Chronic Myeloid Leukemia at a Tertiary Center

Outcomes of Blast-Phase MPN and JAK2 , MPL , and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2 , MPL , and CALR Genes: A Propensity Score-Adjusted Cohort Study

Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study

Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience

Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic

RAS Pathway Mutations Are Associated with Proliferative Features and Frequently Co-Occur with TET2 mutationsin Philadelphia Negative MPN Subtypes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only